Newsroom

LONDON--(BUSINESS WIRE)--  Commonwealth Bank of Australia Issue of EUR 1,000,000,000.00 Floating Rate Notes due December 2027 Series o 6655 Tranche 1 MTN ISSUE NAME. Our Ref. MS2984 ISIN Code. XS2975281903 TOTAL INTEREST AMT. CURRENCY CODE. EUR DAY BASIS. Actual/360 (A004) NUM OF DAYS. 91 INTEREST RATE. 2.455 PCT VALUE DATE. 15/09/2025 INTEREST PERIOD. 16/06/2025 TO 15/09/2025 EUR 6,205,694.44 POOL FACTOR. N/A...

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: First Pacific Advisors, LP (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be nam...

LONDON--(BUSINESS WIRE)--  City Of Goteborg Issue of SEK 1,000,000,000.00 Green Floating Rate Notes Due March 2027 Series no GB17 Tranche 1 MTN ISSUE NAME. Our Ref. MN4473 ISIN Code. XS2317289291 TOTAL INTEREST AMT. CURRENCY CODE. SEK DAY BASIS. Actual/360 (A004) NUM OF DAYS. 92 INTEREST RATE. 3.199 PCT VALUE DATE. 16/09/2025 INTEREST PERIOD. 16/06/2025 TO 16/09/2025 SEK 8,175,222.22 POOL FACTOR. N/A...

LONDON--(BUSINESS WIRE)--  City Of Goteborg Issue of SEK 1,800,000,000.00 Floating Rate Notes due September 2026 Series 2022 01 Tranche 1 MTN ISSUE NAME. Our Ref. MP1188 ISIN Code. XS2556664287 TOTAL INTEREST AMT. CURRENCY CODE. SEK DAY BASIS. Actual/360 (A004) NUM OF DAYS. 92 INTEREST RATE. 2.949 PCT VALUE DATE. 16/09/2025 INTEREST PERIOD. 16/06/2025 TO 16/09/2025 SEK 13,565,400 POOL FACTOR. N/A...

LONDON--(BUSINESS WIRE)--  Commonwealth Bank of Australia Issue of USD 25,000,000.00 Collared Floating Rate Notes due 20 March 2034 Series 6579 Tranche 1 MTN ISSUE NAME. Our Ref. MQ8179 ISIN Code. XS2787874192 TOTAL INTEREST AMT. CURRENCY CODE. USD DAY BASIS. 30/360 BOND BASIS (A001) NUM OF DAYS. 90 INTEREST RATE. 5.41315 PCT VALUE DATE. 20/06/2025 INTEREST PERIOD. 20/03/2025 TO 20/06/2025 USD 338,321.88 POOL FACTOR. N/A...

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Polaris Capital Management, LLC (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must b...

LYON, France--(BUSINESS WIRE)--Regulatory News: MaaT Pharma (EURONEXT: MAAT – la “Société”), société de biotechnologies en stade clinique avancé, leader dans le développement de Microbiome Ecosystem TherapiesTM (MET) visant à améliorer la survie des patients atteints de cancers grâce à la modulation du système immunitaire, annonce aujourd’hui que le Professeur Mohamad Mohty, Professeur d’Hématologie et Chef du service d’Hématologie et de Thérapie Cellulaire à l’Hôpital Saint-Antoine et à Sorbon...

LYON, France--(BUSINESS WIRE)--MaaT Pharma Presents Updated Positive Data in Early Access Program for Xervyteg® at the EHA Annual Congress....

LONDON--(BUSINESS WIRE)--Da der weltweite Markt für mobile virtuelle Netzwerkbetreiber (Mobile Virtual Network Operators, MVNO) bis 2030 auf voraussichtlich 137 Milliarden US-Dollar anwachsen soll, stellt eSIM Go, ein Pionier im Bereich digitale Konnektivität, die Weichen für zukünftiges Wachstum. Mit seiner modernisierten Benutzerplattform, die in Zusammenarbeit mit CSG® (NASDAQ: CSGS) entwickelt wurde, wird eSIM Go die MVNO-Einführung vereinfachen und beschleunigen und so ein schnelleres Onbo...

MARSEILLE, France--(BUSINESS WIRE)--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the presentation of preclinical data for IPH6501, its proprietary ANKET® targeting CD20 currently under investigation in a Phase 1/2 study in relapsed and/or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL) (NCT06088654), at the European Hematology Association (EHA) Congress 2025, taking place June 12-15 in Milan, Italy. R-CHOP is an establish...